Clinical trials
Cervical Cancer Screening clinical trials
Below are recruiting cervical cancer screening clinical trials, each written for real people, not researchers. We’re tracking 170 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04093388Recruiting
At-home Pap test to improve cervical screening in rural areas
This study looks at using a self-collected Pap test (a sample you collect yourself) to help people get routine cervical cancer screening. It may help improve screening rates, especially for those in rural areas where getting to a clinic can be harder.
Birmingham, AlabamaAges 21–65 - NCT04107181Recruiting
Speculum-free screening for cervical cancer testing
This pilot study tests a new way to check for cervical cancer that does not use a speculum (a tool used during pelvic exams). If you qualify, you may be offered this alternative screening method as part of the study.
Durham, North CarolinaAges 21–65 - NCT04226313Recruiting
Home self-swab tests for people not doing cervical screening
This study looks at whether a home self-sampling swab can help people who haven’t joined cervical cancer screening in the past few years. If you qualify, you’ll be asked to collect a swab yourself so it can be tested, aiming to make screening easier to access.
OlomoucAges 30–65 - NCT04859530Recruiting
Smartphone AI test for cervical cancer screening
This study checks whether a smartphone-based AI tool can help screen for cervical cancer. You may be offered the AI-assisted screening during a clinic visit to see if it works well when visualizing the cervix.
Dschang, MenouaAges 30–49 - NCT04865887RecruitingPhase 2
Pembrolizumab plus lenvatinib for advanced cervical cancer
This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04916990Recruiting
Care program for rural adults with several lung and head cancers
This study looks at how to improve care for adults with certain cancers who live in rural areas and may face access problems. It mainly focuses on people receiving cancer treatment at specific Colorado-area hospitals, and who are uninsured or underinsured.
Aurora, ColoradoAges 18–99 - NCT05086692RecruitingPhase 1/Phase 2
Beta-only IL-2 therapy for advanced solid tumors
This Phase 1/2 study tests a beta-only version of IL-2, an immune-stimulating treatment, to shrink or control advanced or metastatic solid tumors. It’s mainly designed to check safety and to see if it can help patients by improving tumor response.
San Diego, CaliforniaAges 18 years+ - NCT05286034Recruiting
AI chatbot to help women join cervical screening
This trial tests whether an AI chatbot can encourage women to take part in cervical cancer screening. It targets women who have not had a recent Pap test and who did not respond to an invitation letter, aiming to improve participation.
CarcassoneAges 30–65 - NCT05372484Recruiting
Test technology to improve cervical cancer screening and diagnosis
This study tests a new technology to help find cervical cancer earlier by focusing on people who already had an abnormal screening result. It may help improve how abnormal tests are checked and diagnosed.
Houston, TexasAges 25–49 - NCT05413798Recruiting
Urine HPV test for cervical cancer screening in HIV
This study looks at whether testing for HPV (the virus that can lead to cervical cancer) using a urine sample can help with cervical cancer screening. It’s for women living with HIV, who may be at higher risk and need effective, easy screening.
Westdene, JohannesburgAges 25 years+ - NCT05483491RecruitingPhase 1
TCR cell therapy for select metastatic cancers
This Phase 1 trial tests a personalized immune-cell treatment (TCR-T cells) for certain metastatic cancers. It targets cancers that carry a specific marker and requires patients to have a specific immune-system match, aiming to improve cancer control when standard options were already tried.
New Brunswick, New JerseyAges 18 years+ - NCT05544084Recruiting
Patient navigation program for cervical screening in Senegal
This study tests a patient “navigator” approach to improve cervical cancer screening and prevention access in Senegal. You may be invited to help through community education, health facility work, or by being part of a screening-support household.
DakarAges 25–69 - NCT05572944Recruiting
Using family risk to predict lung cancer in never-smokers
This study builds and tests risk prediction tools for lung cancer in people who have never smoked, using information from family history. If it works, it may help doctors identify who might need closer screening earlier.
Taichung, TaiwanAges 20–80 - NCT05606133Recruiting
Test HPV DNA from blood to track cervical cancer risk
This study looks at a blood test that measures HPV DNA to help screen and monitor people with HPV-related cervical problems. If you have confirmed high-grade cervical changes or cervical cancer, the test may help doctors follow how your condition changes over time.
New York, New YorkAges 18 years+ - NCT05686226RecruitingPhase 2
Trial tests immune cells targeting HPV-16 cancers
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
Bethesda, MarylandAges 18 years+ - NCT05817214RecruitingPhase 2
Immunotherapy plus targeted drug for advanced cervical cancer
This Phase 2 trial tests cadonilimab (an immunotherapy medicine) combined with anlotinib (a targeted drug) for advanced or recurrent cervical cancer that has already been treated. It may help shrink tumors or slow cancer growth, especially if the cancer has a measurable area doctors can track.
Wuhan, HubeiAges 18–75 - NCT06042543Recruiting
Cervical cancer screening trial for unscreened women
This trial tests a new, affordable way to screen for cervical cancer that can be done in low- and middle-income countries. It uses artificial intelligence to help decide who needs follow-up care.
Cincinnati, OhioAges 25–49 - NCT06082765Recruiting
Cervical cancer screening with menstrual blood test
This trial tests if a new DNA test (NGS-HPV) using menstrual blood can detect HPV and help screen for cervical cancer. You may participate if you have regular periods and plan to get cervical screening.
Wuhan, HubeiAges 20–60 - NCT06123884RecruitingPhase 2/Phase 3
BAT1308 plus chemotherapy for PD-L1-positive cervical cancer
This clinical trial tests a new combination therapy (BAT1308 plus chemotherapy, with or without Avastin) for women with advanced cervical cancer that is PD-L1-positive and has not been previously treated with systemic therapy. The goal is to see if this combination can shrink tumors or slow disease progression.
Wuhan, HubeiAges 18–70 - NCT06155396RecruitingPhase 2
Targeted drug combo for advanced cervical cancer
This trial tests a combination of two drugs: an antibody-drug conjugate (RC48-ADC) that targets HER2 on cancer cells, plus an immunotherapy (Zimberelimab) that helps your immune system attack the cancer. It is for people with advanced cervical cancer whose prior platinum-based chemotherapy has stopped working.
Bengbu, AnhuiAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+ - NCT06254846Recruiting
Urine test for HPV cervical cancer screening
This study tests if a urine sample can replace a cervical swab for HPV testing during cervical cancer screening. If it works, it could make screening easier and less uncomfortable.
Saint-EtienneAges 30–65 - NCT06459687RecruitingPhase 3
Socazolimab for first-line treatment of advanced cervical cancer
This phase 3 trial tests a new immunotherapy drug called socazolimab combined with chemotherapy as a first treatment for cervical cancer that has come back, spread, or cannot be removed with surgery or radiation. The goal is to see if it helps shrink tumors and improves survival.
Hefei, AnhuiAges 18–75 - NCT06527456Recruiting
Boosting cervical cancer screening with help from your doctor
This study tests whether extra support from your regular general practitioner can help more women get screened for cervical cancer. If you qualify, your GP will work with you to make sure you don't miss your screening appointment.
CréteilAges 25–65
Hear when a new Cervical Cancer Screening trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cervical cancer screening?
- Yes. Clin2 currently lists 170 recruiting cervical cancer screening studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cervical cancer screening trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cervical cancer screening trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.